Crinecerfont in Adult Congenital Adrenal Hyperplasia

Crinecerfont in Adult Congenital Adrenal Hyperplasia

To the Editor: In the phase 3 CAHtalyst trial reported by Auchus et al. (Aug. 8 issue), 1 the use of crinecerfont allowed for a greater reduction in the mean daily glucocorticoid dose than placebo (between-group difference, −2.7 mg per square meter of body-surface area per day) in patients with cong...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 391; no. 16; pp. 1556 - 1558
Main Authors: Pousada-Fonseca, Álvaro, Pedreira-Bouzas, Jorge, Jaschke, Nikolai P., Auchus, Richard J., Sturgeon, Julia, Lin, Vivian H.
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 24-10-2024
Subjects:
Androgens
Conflicts of interest
Cortisol
Hormones
Hyperplasia
Insulin
Neutrophils
Pediatrics
Madrid Spain
Spain
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To the Editor: In the phase 3 CAHtalyst trial reported by Auchus et al. (Aug. 8 issue), 1 the use of crinecerfont allowed for a greater reduction in the mean daily glucocorticoid dose than placebo (between-group difference, −2.7 mg per square meter of body-surface area per day) in patients with congenital adrenal hyperplasia (CAH). The authors established 11 mg per square meter per day as the physiologic threshold, a value that corresponds to the 95th percentile of cortisol production in healthy persons studied by Purnell et al. 2 In that same study, the mean cortisol production rate was 7 mg per square . . .
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
ObjectType-Commentary-2
content type line 23
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc2411263